Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Collaboration › Details

Sarepta–Centogene: molecular diagnostics, 201902–202002 collab service identifying DMD patients in MENA region by Centogene

 

Period Period 2019-02-28 ï¿½ 2020-02-28
Organisations Partner, 1st Sarepta Therapeutics Inc. (NASDAQ: SRPT)
  Partner, 2nd Centogene AG
  Group Centogene (Group)
Products Product molecular diagnostics
  Product 2 CentoCard® dried blood spot collection kit
     

Centogene AG. (2/28/19). "Press Release: Centogene Announces Strategic Collaboration with Sarepta Therapeutics". Rostock.

Agreement focused on identification of patients with Duchenne muscular dystrophy (DMD)


CENTOGENE today announced a 12-month strategic collaboration with Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for the identification of patients with Duchenne muscular dystrophy (DMD) in the Middle East and North Africa region.

CENTOGENE will perform complete molecular diagnostic testing using deletion/duplication analysis and full length sequencing of the DMD gene in MLPA negative patients. Under the terms of the agreement with Sarepta, CENTOGENE will also provide diagnostic services to physicians treating patients exhibiting symptoms related to DMD. Physicians can submit a patient sample via CentoCard® - CENTOGENE’s proprietary, validated dried blood spot collection kit, using a small amount of blood.

“Our collaboration with Sarepta Therapeutics further demonstrates CENTOGENE’s commitment to accelerating the development of new orphan drugs by using our knowledge of the global rare disease market - in particular our expertise in the identification of DMD patients,” commented Dr. Arndt Rolfs, CEO and founder of CENTOGENE. “Today, as the world recognizes Rare Disease Day and the tremendous challenges that people living with a rare disease face on a daily basis, we remain dedicated to transforming the science of genetic information into solutions and creating hope for patients with rare diseases and their families.”

“Sarepta’s goal is to bring a better life to all eligible individuals with DMD around the globe, and to do so with great expediency. Today’s agreement with CENTOGENE is a step to achieving this goal,” stated Doug Ingram, Sarepta’s president and chief executive officer.

DMD is a genetic disorder affecting approximately 1 in 3,500 to 5,000 newborn boys. The disorder causes progressive weakness and muscle wasting, and is caused by a lack of dystrophin, an essential protein that helps keep muscle cells intact. Muscle weakness becomes increasingly noticeable by age 3 to 5, and most patients use a wheelchair by the time they are 13, having lost the ability to walk. During adolescence, cardiac and respiratory muscle deterioration lead to serious, life-threatening complications.


About CENTOGENE

CENTOGENE is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for patients. We are focused on bringing rationality to treatment decisions and accelerating the development of new orphan drugs by using our knowledge of the global rare disease market, including its epidemiological and clinical heterogeneity and our innovative biomarkers. Our solutions for pharmaceutical partners address the unique challenges across the spectrum of developing and commercializing therapies for rare genetic diseases.

As one of the largest rare disease companies worldwide, CENTOGENE is dedicated to transforming the science of genetic information into solutions and hope for patients with rare diseases and their families.


Contacts

CENTOGENE
Ross Bethell
Director, Corporate Communications
ross.bethell@centogene.com

Press Contact
Lauren Arnold
MacDougall
+1 781-235-3060
larnold@macbiocom.com

   
Record changed: 2019-04-19

Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px

More documents for Sarepta Therapeutics Inc. (NASDAQ: SRPT)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top